Hsbc Holdings PLC acquired a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 145,695 shares of the life sciences company's stock, valued at approximately $25,660,000. Hsbc Holdings PLC owned about 0.10% of Illumina as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of ILMN. Fiduciary Financial Advisors purchased a new stake in Illumina during the second quarter valued at approximately $26,000. Keating Financial Advisory Services Inc. purchased a new position in Illumina in the second quarter worth $32,000. Rakuten Securities Inc. purchased a new position in Illumina in the second quarter worth $33,000. Elyxium Wealth LLC acquired a new position in shares of Illumina during the fourth quarter worth $25,000. Finally, Laurel Wealth Advisors LLC acquired a new position in shares of Illumina during the fourth quarter worth $26,000. Institutional investors own 89.42% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on ILMN. JPMorgan Chase & Co. raised their price objective on Illumina from $220.00 to $230.00 and gave the stock an "overweight" rating in a research report on Friday, July 31st. TD Cowen upped their target price on Illumina from $192.00 to $210.00 and gave the company a "hold" rating in a research report on Friday, July 31st. Citigroup increased their price target on Illumina from $95.00 to $113.00 and gave the company a "sell" rating in a research note on Monday, August 3rd. Guggenheim raised their price target on Illumina from $200.00 to $226.00 and gave the stock a "buy" rating in a report on Friday, July 31st. Finally, Piper Sandler restated an "overweight" rating and set a $225.00 price target (up from $200.00) on shares of Illumina in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $188.40.
Get Our Latest Research Report on ILMN
Insider Buying and Selling at Illumina
In other news, SVP Christensen Jakob Wedel sold 1,033 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the transaction, the senior vice president directly owned 14,023 shares of the company's stock, valued at approximately $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the firm's stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $200.00, for a total value of $123,000.00. Following the completion of the transaction, the insider owned 20,338 shares of the company's stock, valued at approximately $4,067,600. The trade was a 2.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 2,034,688 shares of company stock worth $417,970,281. 2.90% of the stock is currently owned by insiders.
Illumina Trading Up 1.3%
NASDAQ ILMN opened at $227.69 on Friday. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $231.81. The company has a fifty day simple moving average of $192.98 and a two-hundred day simple moving average of $155.18. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The stock has a market cap of $34.38 billion, a P/E ratio of 42.48, a P/E/G ratio of 3.16 and a beta of 1.45.
Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating analysts' consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same period in the previous year, the company earned $1.19 earnings per share. The business's quarterly revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current year.
About Illumina
(
Free Report)
Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Further Reading
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
